In a very recent study, Uzawa at co-workers analyzed for the first time the amount of PRDX1, PRDX5 and PRDX6 in CSF and serum of patients with MS, neuromyelitis optica spectrum disorder (NMOSD), and other neurological disorders (ONDs). Here, PRDX6 is linked to myeloid sarcoma.